Nuclidium

Data updated Nov 22, 2026Money ledger: 2 records from 2 sourcesAnnounced 2Full reportReport a mistake

Facts

as of Nov 22, 2026

Setting a New Standard in Precision Oncology. Next-generation copper-based radiopharmaceuticals enable the highest accuracy and accessibility for targeted cancer treatment.

Legal name
Dr. Daniel Parera Nuclidium GmbH
Headquarters
Munich, Germany
Employees
51-200estimated range
Legal entities
2 in 2 countries
Register numbers
HR HRB 262606 · VAT DE342413979

These are the key facts about Nuclidium on Alion as of Nov 22, 2026. Nuclidium is headquartered in Munich, Germany. The latest round is Series B of $88.5M, announced in 2025.

Sources: company registers, GLEIF, Wikidata, the company's site, Alion job postingsReport a mistake

Nuclidium has $88.5M paid in by investors, lenders and donors.

$88.5MPaid in
Money innewest first
Equity raised
May 2026 · Series B
not statedPaid
Equity raised
Jul 2025 · Series B
$88.5MPaid
Money by yearUSD, rounds and grants
2026-1 record
2025$88.5M1 record
Every row links its own source. A flow two sources state counts once; a figure a source does not state reads "not stated".

Nuclidium operates through 2 legal entities in 2 countries.

Legal entities2 in 2 countries
Dr. Daniel Parera Nuclidium GmbH
operator
DE
Nuclidium AG
related
CH
Holders and shares as each register or filing states them.

Nuclidium in public registers.

Legal entity active
Dr. Daniel Parera Nuclidium GmbH
Not checked
Sanctions lists
OFAC SDN, EU consolidated
No match
Phishing reports
OpenPhish, Phishing.Database
None
Patents
6
Full employer checkScam signs in adverts, mail records, visa registers, domain history
Sources: company registers, the Alion truth index, OFAC and EU sanctions lists, US WARN notices
Sources: the outlets named on each headline, each story once

Footprint

Hiring in 1 city in 1 country.

1Cities
1Countries
SiteTypeOpen rolesHires most forEngineering
Munich GermanyHeadquarters0
Source: office addresses in postings and company registers